Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263

Small cell lung cancer (SCLC) has an annual mortality approaching that of breast and prostate cancer. Although sensitive to initial chemotherapy, SCLC rapidly develops resistance, leading to less effective second-line therapies. SCLC cells often overexpress Bcl-2, which protects cells from apoptosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, E F, McColl, K S, Zhong, F, Wildey, G, Dowlati, A, Distelhorst, C W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720890/
https://www.ncbi.nlm.nih.gov/pubmed/26720343
http://dx.doi.org/10.1038/cddis.2015.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720890/
https://www.ncbi.nlm.nih.gov/pubmed/26720343
http://dx.doi.org/10.1038/cddis.2015.355

Ejemplares similares